(Q38735563)

English

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

scientific article published on 31 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial (English)

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

17

object named as

Jeffrey Schlom

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

James L. Gulley

18

object named as

James L Gulley

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

author name string

Christopher R Heery

1

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Geraldine O'Sullivan-Coyne

2

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Ravi A Madan

3

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lisa Cordes

4

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Arun Rajan

5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Myrna Rauckhorst

6

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Elizabeth Lamping

7

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Israel Oyelakin

8

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Jennifer L Marté

9

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lauren M Lepone

10

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Renee N Donahue

11

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Italia Grenga

12

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Jean-Marie Cuillerot

13

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Berend Neuteboom

14

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Anja von Heydebreck

15

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Kevin Chin

16

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

publication date

31 March 2017

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

18

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

587-598

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Thymic carcinoma associated with paraneoplastic polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiorgan autoimmune manifestations associated with thymoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Thymoma-associated paraneoplastic polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical immunotoxicity of therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of charge on antibody tissue distribution and pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930239-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28373007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(17)30239-5

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2019

http://europepmc.org/abstract/PMC/6387686

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38735563&oldid=1781621539"